Clovis Oncology (CLVS) Misses Q4 EPS Views
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Mizuho Securities Remains Sidelined on Clovis Oncology (CLVS) Ahead of ODAC Panel
February 29, 2016 7:45 AM ESTMizuho Securities reiterated a Neutral rating on Clovis Oncology (NASDAQ: CLVS), and cut the price target to $21.00 (from $23.00), ahead of an ODAC Panel, scheduled for April 12th. Mizuho expects examination of dosing, response rates, patient characteristics and duration of therapy to be key... More
